Biomarkers in Cancer Staging, Prognosis and Treatment Selection (original) (raw)

• Sobin, L. H. TNM: evolution and relation to other prognostic factors. Semin. Surg. Oncol. 21, 3–7 (2003). Historical perspective of the TNM staging guidelines.
  Article PubMed Google Scholar
• Hammond, M. E. & Taube, S. E. Issues and barriers to development of clinically useful tumor markers: a development pathway proposal. Semin. Oncol. 29, 213–221 (2002). Provides useful guidelines for the discovery, evaluation and validation of clinical biomarkers.
  Article PubMed Google Scholar
• Negm, R. S., Verma, M. & Srivastava, S. The promise of biomarkers in cancer screening and detection. Trends Mol. Med. 8, 288–293 (2002).
  Article CAS PubMed Google Scholar
• US Department of Health & Human Services; US Food and Drug Administration. Challenge and Opportunity on the Critical Path of New Medical Products. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html (2004).
• Anderson, N. L. & Anderson, N. G. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 1, 845–867 (2002).
  Article CAS PubMed Google Scholar
• Nishizuka, S. et al. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res. 63, 5243–5250 (2003). Clear demonstration that numerous genomic, proteomic and tissue-based arrays can be used in concert to distinguish between colon and ovarian carcinomas.
  CAS PubMed Google Scholar
• Leong, P. P. et al. Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. J. Natl Cancer Inst. 90, 972–977 (1998).
  Article CAS PubMed Google Scholar
• Califano, J. et al. Unknown primary head and neck squamous cell carcinoma: molecular identification of the site of origin. J. Natl Cancer Inst. 91, 599–604 (1999).
  Article CAS PubMed Google Scholar
• Califano, J. et al. Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin. Cancer Res. 6, 347–352 (2000).
  CAS PubMed Google Scholar
• Ma, X. et al. Gene expression profiles of human breast cancer progression. Proc. Natl Acad. Sci. USA 100, 5974–5979 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Abulafia, O. & Sherer, D. M. Automated cervical cytology: meta-analyses of the performance of the PAPNET system. Obst. Gynecol. Surv. 54, 253–264 (1999).
  Article CAS Google Scholar
• Destounis, S. V. et al. Can computer-aided detection with double reading of screening mammograms help decrease the false-negative rate? Initial experience. Radiology 232, 578–584 (2004).
  Article PubMed Google Scholar
• Awai, K. et al. Pulmonary nodules at chest CT: effect of computer-aided diagnosis on radiologists' detection performance. Radiology 230, 347–352 (2004).
  Article PubMed Google Scholar
• Erickson, B. J. & Bartholmai, B. Computer-aided detection and diagnosis at the start of the third millennium. J. Digit. Imaging 15, 59–68 (2002).
  Article PubMed PubMed Central Google Scholar
• American Joint Committee on Cancer & American Cancer Society. AJCC Cancer Staging Handbook: from the AJCC Cancer Staging Manual (eds Greene, F. L. et al.) (Springer, New York, 2002). AJCC guidelines for cancer staging.
• McQuade, P. & Knight, L. C. Radiopharmaceuticals for targeting the angiogenesis marker αvβ3 . Q. J. Nucl. Med. 47, 209–220 (2003).
  CAS PubMed Google Scholar
• Blankenberg, F. G. et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc. Natl Acad. Sci. USA 95, 6349–6354 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Kuge, Y. et al. Feasibility of 99mTc-annexin V for repetitive detection of apoptotic tumor response to chemotherapy: an experimental study using a rat tumor model. J. Nucl. Med. 45, 309–312 (2004).
  CAS PubMed Google Scholar
• Krohn, K. A. Evaluation of alternative approaches for imaging cellular growth. Q. J. Nucl. Med. 45, 174–178 (2001).
  CAS PubMed Google Scholar
• Kostakoglu, L., Agress, H. Jr & Goldsmith, S. J. Clinical role of FDG PET in evaluation of cancer patients. Radiographics 23, 315–340 (2003).
  Article PubMed Google Scholar
• Kostakoglu, L. & Goldsmith, S. J. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J. Nucl. Med. 44, 224–239 (2003).
  PubMed Google Scholar
• Britz-Cunningham, S. H. & Adelstein, S. J. Molecular targeting with radionuclides: state of the science. J. Nucl. Med. 44, 1945–1961 (2003).
  CAS PubMed Google Scholar
• Agrawal, M. et al. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin. Cancer Res. 9, 650–656 (2003).
  CAS PubMed Google Scholar
• Revillion, F., Bonneterre, J. & Peyrat, J. P. ERBB2 oncogene in human breast cancer and its clinical significance. Eur. J. Cancer 34, 791–808 (1998).
  Article CAS PubMed Google Scholar
• Press, M. F. et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res. 54, 5675–5682 (1994).
  CAS PubMed Google Scholar
• Singletary, S. E. et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J. Clin. Oncol. 20, 3628–3636 (2002).
  Article PubMed Google Scholar
• Druker, B. J. et al. Activity of a specific inhibitor of the BCR–ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038–1042 (2001).
  Article CAS PubMed Google Scholar
• Balmain, A., Gray, J. & Ponder, B. The genetics and genomics of cancer. Nature Genet. 33 (Suppl.), 238–244 (2003).
  Article CAS PubMed Google Scholar
• Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004).
  Article CAS PubMed Google Scholar
• Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004). Evidence that subtle mutations in EGFR can affect the clinical response to gefitinib.
  Article CAS PubMed Google Scholar
• Kaneda, H. et al. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer. Lung Cancer 46, 247–254 (2004).
  Article PubMed Google Scholar
• Ravdin, P. M. et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J. Clin. Oncol. 19, 980–991 (2001).
  Article CAS PubMed Google Scholar
• Relling, M. & Dervieux, T. Pharmacogenetics and cancer therapy. Nature Rev. Cancer 1, 99–108 (2001).
  Article CAS Google Scholar
• Lenz, H. J. The use and development of germline polymorphisms in clinical oncology. J. Clin. Oncol. 22, 2519–2521 (2004).
  Article CAS PubMed Google Scholar
• Leon, S. A., Shapiro, B., Sklaroff, D. M. & Yaros, M. J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37, 646–650 (1977).
  CAS PubMed Google Scholar
• Sidransky, D. Emerging molecular markers of cancer. Nature Rev. Cancer 2, 210–219 (2002). In-depth review of diverse biomarkers undergoing clinical evaluation.
  Article CAS Google Scholar
• Kahn, H. J. et al. Enumeration of circulating tumor cells in the blood of breast cancer patients after filtration enrichment: correlation with disease stage. Breast Cancer Res. Treat. 86, 237–247 (2004).
  Article PubMed Google Scholar
• Stathopoulou, A. et al. Real-time quantification of CK-19 mrna-positive cells in peripheral blood of breast cancer patients using the lightcycler system. Clin. Cancer Res. 9, 5145–5151 (2003).
  CAS PubMed Google Scholar
• Hoon, D. S. et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res. 60, 2253–2257 (2000).
  CAS PubMed Google Scholar
• Muller, V. & Pantel, K. Bone marrow micrometastases and circulating tumor cells: current aspects and future perspectives. Breast Cancer Res. 6, 258–261 (2004).
  Article PubMed PubMed Central Google Scholar
• Pantel, K. & Brakenhoff, R. H. Dissecting the metastatic cascade. Nature Rev. Cancer 4, 448–456 (2004).
  Article CAS Google Scholar
• Meng, S. et al. Circulating tumor cells in patients with breast cancer dormancy. Clin. Cancer Res. 10, 8152–8162 (2004).
  Article PubMed Google Scholar
• Brennon, J. A. et al. Molecular assesment of histopathological staging in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 332, 429–435 (1995).
  Article Google Scholar
• Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 88, 323–331 (1997).
  Article CAS PubMed Google Scholar
• Nigro, J. M., et al. Mutations in the p53 gene occur in diverse tumor types. Nature 342, 705–708 (1989).
  Article CAS PubMed Google Scholar
• Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786–792 (2005).
  Article CAS PubMed Google Scholar
• Merlo, A. et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Med. 1, 686–692 (1995).
  Article CAS PubMed Google Scholar
• Herman, J. G. et al. Silencing of the VHL tumor-suppressor gene by dna methylation in renal carcinoma. Proc. Natl Acad. Sci. USA 91, 9700–9704 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Jenuwein, T. & Allis, C. Translating the histone code. Science 293, 1074–1080 (2001).
  Article CAS PubMed Google Scholar
• Esteller, M., Corn, P. G., Baylin, S. B. & Herman, J. G. A gene hypermethylation profile of human cancer. Cancer Res. 61, 3225–3229 (2001).
  CAS PubMed Google Scholar
• Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D. & Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA 93, 9821–9826 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Frommer, M. et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual dna strands. Proc. Natl Acad. Sci. USA 89, 1827–1831 (1992).
  Article CAS PubMed PubMed Central Google Scholar
• Jeronimo, C. et al. Quantitation of GTSP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Natl Cancer Inst. 93, 1747–1752 (2001).
  Article CAS PubMed Google Scholar
• Rosas, S. L. et al. Promoter hypermethylation patterns of p16, o6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res. 61, 939–942 (2001).
  CAS PubMed Google Scholar
• Belinsky, S. A. et al. Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl Acad. Sci. USA 95, 11891–11896 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Palmisano, W. A. et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60, 5954–5958 (2000).
  CAS PubMed Google Scholar
• Ahrendt, S. A. et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J. Natl Cancer Inst. 91, 332–339 (1999).
  Article CAS PubMed Google Scholar
• Ramirez, J. L. et al. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Lett. 193, 207–216 (2003).
  Article CAS PubMed Google Scholar
• Usadel, H. et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res. 62, 371–375 (2002).
  CAS PubMed Google Scholar
• Valenzuela, M. T. et al. Assessing the use of p16INK4a promoter gene methylation in serum for detection of bladder cancer. Eur. Urol. 42, 622–630 (2002).
  Article CAS PubMed Google Scholar
• Nakayama, H. et al. Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients. Int. J. Cancer 105, 491–493 (2003).
  Article CAS PubMed Google Scholar
• Yamaguchi, S., Asao, T., Nakamura, J. I., Ide, M. & Kuwano, H. High frequency of DAP-kinase gene promoter methylation in colorectal cancer specimens and its identification in serum. Cancer Lett. 194, 99–105 (2003).
  Article CAS PubMed Google Scholar
• Esteller, M. et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl J. Med. 343, 1350–1354 (2000).
  Article CAS PubMed Google Scholar
• Weinstein, J. N. Pharmacogenomics — teaching old drugs new tricks. N. Engl. J. Med. 343, 1408–1409 (2000).
  Article CAS PubMed Google Scholar
• Esteller, M. DNA methylation and cancer therapy: new developments and expectations. Curr. Opin. Oncol. 17, 55–60 (2005).
  Article CAS PubMed Google Scholar
• Cheng, J. C. et al. Preferential response of cancer cells to zebularine. Cancer Cell 6, 151–158 (2004).
  Article CAS PubMed Google Scholar
• Piekarz, R. & Bates, S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr. Pharm. Des. 10, 2289–2298 (2004).
  Article CAS PubMed Google Scholar
• Piekarz, R. L. et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 103, 4636–4643 (2004).
  Article CAS PubMed Google Scholar
• Mischel, P. S., Cloughesy, T. F. & Nelson, S. F. DNA-microarray analysis of brain cancer: molecular classification for therapy. Nature Rev. Neurosci. 5, 782–792 (2004).
  Article CAS Google Scholar
• Gray, J. W. & Collins, C. Genome changes and gene expression in human solid tumors. Carcinogenesis 21, 443–452 (2000).
  Article CAS PubMed Google Scholar
• Velculescu, V. E., Zhang, L., Vogelstein, B. & Kinzler, K. W. Serial analysis of gene expression. Science 270, 484–487 (1995).
  Article CAS PubMed Google Scholar
• Weigl, B. H., Bardell, R. L. & Cabrera, C. R. Lab-on-a-chip for drug development. Adv. Drug. Deliv. Rev. 55, 349–377 (2003).
  Article CAS PubMed Google Scholar
• Weinstein, J. N. et al. An information-intensive approach to the molecular pharmacology of cancer. Science 275, 343–349 (1997).
  Article CAS PubMed Google Scholar
• Papin, J. A, Hunter, T., Palsson, B. O. & Subramaniam, S. Reconstruction of cellular signalling networks and analysis of their properties. Nature Rev. Mol. Cell Biol. 6, 99–111 (2005).
  Article CAS Google Scholar
• Petricoin, E. F., Zoon, K. C., Kohn, E. C., Barrett, J. C. & Liotta, L. A. Clinical proteomics: translating benchside promise into bedside reality. Nature Rev. Drug Discov. 1, 683–695 (2002). Comprehensive review of clinical proteomic technologies and associated pattern-based protein markers.
  Article CAS Google Scholar
• Perou, C. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000).
  Article CAS PubMed Google Scholar
• Sorlie, T., Perou, C., Brown, P., Botstein, D. & Borresen-Dale, A. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869–10874 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Sotiriou, C. et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl Acad. Sci. USA 100, 10393–10398 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999–2009 (2002).
  Article CAS PubMed Google Scholar
• van't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530–536 (2002).
  Article CAS Google Scholar
• Chang, J. C. et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362, 362–369 (2003).
  Article CAS PubMed Google Scholar
• Sotiriou, C. et al. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res. 4, R3 (2002).
• Ramaswamy, S., Ross, K., Lander, E. & Golub, T. A molecular signature of metastasis in primary solid tumors. Nature Genet. 33, 49–54 (2003).
  Article CAS PubMed Google Scholar
• Rosell, R. et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 10, 1318–1325 (2004).
  Article CAS PubMed Google Scholar
• Salonga, D. et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 6, 1322–1327 (2000).
  CAS PubMed Google Scholar
• Bittner, M. et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406, 536–540 (2000).
  Article CAS PubMed Google Scholar
• Carr, K. M., Bittner, M. & Trent, J. M. Gene-expression profiling in human cutaneous melanoma. Oncogene 22, 3076–3080 (2003).
  Article CAS PubMed Google Scholar
• Golub, T. R. et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531–537 (1999).
  Article CAS PubMed Google Scholar
• Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503–511 (2000).
  Article CAS PubMed Google Scholar
• Lossos, I. S. et al. Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc. Natl Acad. Sci. USA 99, 8886–8891 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Garber, M. E. et al. Diversity of gene expression in adenocarcinoma of the lung. Proc. Natl Acad. Sci. USA 98, 13784–13789 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Best, C. J. et al. Molecular differentiation of high- and moderate-grade human prostate cancer by cDNA microarray analysis. Diagn. Mol. Pathol. 12, 63–70 (2003).
  Article CAS PubMed Google Scholar
• Zou, T. T. et al. Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon. Oncogene 21, 4855–4862 (2002).
  Article CAS PubMed Google Scholar
• Zhou, G. et al. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol. Cell. Proteomics 1, 117–124 (2002).
  Article CAS PubMed Google Scholar
• Nishizuka, S. et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc. Natl Acad. Sci. USA 100, 14229–14234 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Paweletz, C. P. et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20, 1981–1989 (2001).
  Article CAS PubMed Google Scholar
• Verma, M., Wright, G. L. Jr, Hanash, S. M., Gopal-Srivastava, R. & Srivastava, S. Proteomic approaches within the NCI early detection research network for the discovery and identification of cancer biomarkers. Ann. NY Acad. Sci. 945, 103–115 (2001).
  Article CAS PubMed Google Scholar
• Wulfkuhle, J. D., Liotta, L. A. & Petricoin, E. F. Proteomic applications for the early detection of cancer. Nature Rev. Cancer 3, 267–275 (2003).
  Article CAS Google Scholar
• Sano, T., Smith, C. L. & Cantor, C. R. Immuno-PCR: very sensitive antigen detection by means of specific antibody–DNA conjugates. Science 258, 120–122 (1992).
  Article CAS PubMed Google Scholar
• Nam, J. M., Thaxton, C. S. & Mirkin, C. A. Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science 301, 1884–1886 (2003).
  Article CAS PubMed Google Scholar
• Service, R. F. American Chemical Society Meeting. Tiny transistors scout for cancer. Science 300, 242–243 (2003).
  CAS PubMed Google Scholar
• Seydel, C. Quantum dots get wet. Science 300, 80–81 (2003).
  Article CAS PubMed Google Scholar
• Wu, X. et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nature Biotechnol. 21, 41–46 (2003).
  Article CAS Google Scholar
• Ben-Ari, E. T. Nanoscale quantum dots hold promise for cancer applications. J. Natl Cancer Inst. 95, 502–504 (2003).
  Article PubMed Google Scholar
• Igor, M. et al. Self-assembled nanoscale biosensors based on quantum dot FRET donors. Nature Mater. 2, 630–638 (2003).
  Article CAS Google Scholar
• Wulfkuhle, J. D. et al. Proteomics of human breast ductal carcinoma in situ. Cancer Res. 62, 6740–6749 (2002).
  CAS PubMed Google Scholar
• Wulfkuhle, J. D. et al. New approaches to proteomic analysis of breast cancer. Proteomics 1, 1205–1215 (2001).
  Article CAS PubMed Google Scholar
• Jones, M. B. et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2, 76–84 (2002).
  Article CAS PubMed Google Scholar
• Patel, V., Leethanakul, C. & Gutkind, J. S. New approaches to the understanding of the molecular basis of oral cancer. Crit. Rev. Oral Biol. Med. 12, 55–63 (2001).
  Article CAS PubMed Google Scholar
• Ornstein, D. K. et al. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 21, 2235–2242 (2000).
  Article CAS PubMed Google Scholar
• Pepe, M. S. et al. Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst. 93, 1054–1061 (2001).
  Article CAS PubMed Google Scholar
• Barker, P. E. Cancer biomarker validation: standards and process: roles for the National Institute of Standards and Technology (NIST). Ann. NY Acad. Sci. 983, 142–150 (2003).
  Article CAS PubMed Google Scholar
• Ransohoff, D. F. Rules of evidence for cancer molecular marker discovery and validation. Nature Rev. Cancer 4, 309–314 (2004). Effectively summarizes the problem of data overfitting in discovery-based research and the need for 'rules of evidence' to ensure clinical validity.
  Article CAS Google Scholar
• Gutman, S. Regulatory issues in tumor marker development. Semin. Oncol. 29, 294–300 (2002). Examines the regulatory environment surrounding biomarker approval by the FDA and CMS.
  Article PubMed Google Scholar
• Taube, S. E. & Freiberg, G. P. Regulatory issues related to marker development. Urol. Oncol. 5, 214–216 (2000).
  Article CAS PubMed Google Scholar
• Hackett, J. L. & Lesko, L. J. Microarray data — the US FDA, industry and academia. Nature Biotechnol. 21, 742–743 (2003).
  Article CAS Google Scholar
• Mendelsohn, A. R. & Brent, R. Postgenomic protein analysis: the next bend in the river. Nature Biotechnol. 16, 520–521 (1998).
  Article CAS Google Scholar
• Robson, M. E. et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res. 6, R8–R17 (2004).
• Einspahr, J. G. et al. Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials. Cancer Epidemiol. Biomarkers Prev. 6, 37–48 (1997).
  CAS PubMed Google Scholar
• Togashi, K. Ovarian cancer: the clinical role of US, CT, and MRI. Eur. Radiol. 13 (Suppl. 4), L87–L104 (2003).
  Article PubMed Google Scholar
• Schlieman, M. G., Ho, H. S. & Bold, R. J. Utility of tumor markers in determining resectability of pancreatic cancer. Arch. Surg. 138, 951–956 (2003).
  Article PubMed Google Scholar
• Depres-Brummer, P. et al. The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer. J. Cancer Res. Clin. Oncol. 121, 419–422 (1995).
  Article CAS PubMed Google Scholar
• Duncan, J. L., Price, A. & Rogers, K. The use of CA15.3 as a serum tumour marker in breast carcinoma. Eur. J. Surg. Oncol 17, 16–19 (1991).
  CAS PubMed Google Scholar
• Gion, M. et al. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients. Cancer J. 7, 181–190 (2001).
  CAS PubMed Google Scholar
• Chang, B. L. et al. Polymorphisms in the CYP1A1 gene are associated with prostate cancer risk. Int. J. Cancer 106, 375–378 (2003).
  Article CAS PubMed Google Scholar
• Lee, S. G. et al. Genetic polymorphisms of XRCC1 and risk of gastric cancer. Cancer Lett. 187, 53–60 (2002).
  Article CAS PubMed Google Scholar
• Petrij-Bosch, A. et al. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nature Genet. 17, 341–345 (1997).
  Article CAS PubMed Google Scholar
• Newman, B. et al. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 279, 915–921 (1998).
  Article CAS PubMed Google Scholar
• Wu, X. et al. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J. Natl Cancer Inst. 94, 681–690 (2002).
  Article CAS PubMed Google Scholar
• Bonnen, P. E., Wang, P. J., Kimmel, M., Chakraborty, R. & Nelson, D. L. Haplotype and linkage disequilibrium architecture for human cancer-associated genes. Genome Res. 12, 1846–1853 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Johnson, G. & Todd, J. Haplotype tagging for the identification of common disease genes. Nature Genet. 29, 233–237 (2001).
  Article CAS PubMed Google Scholar
• Hoque, M. O., Lee, C. C., Cairns, P., Schoenberg, M. & Sidransky, D. Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res. 63, 2216–2222 (2003).
  CAS PubMed Google Scholar
• Janne, P. A. et al. High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines. Oncogene 23, 2716–2726 (2004).
  Article CAS PubMed Google Scholar
• Boshoff, C. et al. Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nature Med. 1, 1274–1278 (1995).
  Article CAS PubMed Google Scholar
• To, E. W. H. et al. Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin. Cancer Res. 9, 3254–3259 (2003).
  CAS PubMed Google Scholar
• Leung, S. F. et al. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer 98, 288–291 (2003).
  Article PubMed Google Scholar
• Mueller, N. Overview: viral agents and cancer. Environ. Health Perspect. 103 (Suppl. 8), 259–261 (1995).
  PubMed PubMed Central Google Scholar
• Koutsky, L. A. et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347, 1645–1651 (2002).
  Article CAS PubMed Google Scholar
• Pellet, C. et al. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. J. Invest. Dermatol. 117, 858–863 (2001).
  Article CAS PubMed Google Scholar
• Polyak, K. et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nature Genet. 20, 291–293 (1998).
  Article CAS PubMed Google Scholar
• Bianchi, N. O., Bianchi, M. S. & Richard, S. M. Mitochondrial genome instability in human cancers. Mutat. Res. 488, 9–23 (2001).
  Article CAS PubMed Google Scholar
• Welter, C., Kovacs, G., Seitz, G. & Blin, N. Alteration of mitochondrial DNA in human oncocytomas. Genes Chromosomes Cancer 1, 79–82 (1989).
  Article CAS Google Scholar
• Fliss, M. S. et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 287, 2017–2019 (2000).
  Article CAS PubMed Google Scholar
• Weinstein, J. N. Fishing expeditions. Science 282, 628–629 (1998).
  Article CAS PubMed Google Scholar
• Weinstein, J. N. 'Omic' and hypothesis-driven research in the molecular pharmacology of cancer. Curr. Opin. Pharmacol. 2, 361–365 (2002).
  Article CAS PubMed Google Scholar